Pluvicto approved with an ARPI in PSMA-positive mHSPC: radioligand therapy arrives in first-line metastatic prostate cancer

Novartis said on 31 July 2026 that the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer ^[1]. One sentence moves the first-to-market PSMA radioligand ^[17] out of a post-ARPI, chemotherapy-deferring or post-taxane slot ^[4] and into the first metastatic setting a prostate cancer patient ever reaches. Novartis says the change nearly doubles the eligible population — a company estimate, relayed by Endpoints News on 3 August 2026, with no independent epidemiological source behind it in the records reviewed ^[2].

What happened, precisely

The approval is documented in Novartis's own release, dated 31 July 2026 from Basel, which frames it as "advancing potential new standard of care across metastatic disease" ^[1]. Endpoints News reported it on 3 August 2026 ^[2].

The FDA's own record has not caught up in the sources Prognyx reviewed. Drugs@FDA confirms the application exists — NDA 215833, Pluvicto, Novartis — but the retrieved record carries no approval letter or supplement detail ^[3]. The Prescribing Information on DailyMed still reads: indicated for adult patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with ARPI therapy and are considered appropriate to delay taxane-based chemotherapy, or have received prior taxane-based chemotherapy ^[4]. Until that supplement posts, the exact approved wording — the thing every competitor actually needs — exists only inside Novartis and the agency.

What the release does not say is as operationally loaded as what it does. It names the ARPI class, not an agent, so whether the label is class-level or specifies abiraterone, enzalutamide, apalutamide or darolutamide is unresolved ^[1]. There is no cycle count to compare against the six-cycle castration-resistant regimen, no PSMA-positivity definition or imaging agent, no statement on de novo versus metachronous or high- versus low-volume disease. And there is no efficacy: no radiographic progression-free survival, no overall survival, no hazard ratio, no comparator arm. The registrational trial supporting the approval is not identified in any record available for this briefing.

Why it matters

Line placement is the whole story. Pluvicto's mechanism has not changed — it is a glutamate carboxypeptidase II binding agent, listed in ChEMBL at maximum phase 4 ^[5]. What changed is where in the sequence it sits, and the entire PSMA competitive set has spent three years positioning against the old answer.

The clearest artifact of that is Janux Therapeutics' filing of 2 December 2024, which states that the Phase 1b expansion of JANX007, a PSMA-directed T-cell engager, is "directed at pre-PLUVICTO 2L / 3L patients" ^[18]. In 16 heavily pretreated patients with a median of four prior lines, Janux reported 100% best PSA50 declines, 63% PSA90 and 31% PSA99; 75% maintained PSA50 and 50% maintained PSA90 at twelve weeks or more; 50% objective response (4 of 8) and 63% disease control (5 of 8) in RECIST-evaluable patients, with cytokine release syndrome and treatment-related events primarily in cycle 1 at grades 1-2 and the maximum tolerated dose not reached ^[18]. Janux also noted responses irrespective of resistance driver aberration status or prior taxane or ARPI exposure ^[18]. That is 2024 data, the latest in the records reviewed — but the strategic point is structural: "pre-Pluvicto" now means something earlier and rarer than it did on 30 July 2026.

Two constraints travel with the move. Delivery: radioligand therapy runs through nuclear-medicine theranostic centres, and a survey of high-end centres published on 21 July 2026 describes radiopharmaceutical therapy as "becoming a cornerstone of cancer treatments" with the approvals of 177Lu-PSMA (Pluvicto), 177Lu-DOTATATE (Lutathera) and 223Ra-dichloride (Xofigo) ^[15]. No source in this briefing quantifies Novartis's lutetium-177 output or the number of US treatment sites, so whether a doubled eligible population can physically be dosed is unresolved.

Tolerability is the second. A FAERS disproportionality analysis published on 17 February 2025 opens by stating that the real-world safety profile of 177Lu-PSMA-617 "has not been systemically evaluated" ^[13], and the field was still publicly asking what real-world discontinuation rates look like in January 2026 ^[12] — headline only; the figure was not retrieved. In castration-resistant disease, toxicity trades against a short horizon. In hormone-sensitive disease, patients live longer, the alternatives are oral, and the tolerance for discontinuation is lower.

The Europe divergence

FirstWord Pharma reported on 24 April 2026 that Novartis pulled its bid to broaden Pluvicto's use after EU pushback ^[6], timing that coincides with the CHMP meeting of 20-23 April 2026 ^[7]. Only headlines are available: the specific withdrawn indication and the stated grounds are not in the retrieved text, and Prognyx has not seen the EMA withdrawal document. Four days later, Fierce Pharma reported that Novartis stood by a roughly $5 billion peak-sales ambition despite the European setback and bispecific competition ^[8] — again a headline, not a Novartis primary statement. If the withdrawn European application covered the same expansion the FDA has now granted, two regulators reached opposite conclusions on one package. That is the highest-value question in this story, and no primary document in this briefing settles it.

Who is exposed — by name

The following comes from registry listings, which state what a company is testing and never how well it works.

Beta-emitting PSMA radioligands in late-stage castration-resistant disease. Curium runs a Phase 3 of 177Lu-PSMA-I&T against abiraterone with prednisone or enzalutamide (NCT05204927, active but no longer recruiting) ^[19]. POINT Biopharma, now a wholly owned Lilly subsidiary, runs a Phase 3 of [Lu-177]-PNT2002 after second-line hormonal treatment (NCT04647526, active but no longer recruiting) ^[20]. Telix runs ProstACT Global, a Phase 3 of 177Lu-TLX591 plus standard of care versus standard of care alone, with enzalutamide, abiraterone and docetaxel among the listed interventions (NCT06520345, recruiting) ^[21]. All three are built for a population that has now been partly moved upstream — and part of which will arrive radioligand-experienced.

Alpha emitters. Fusion Pharmaceuticals runs three Phase 2 studies of FPI-2265 (225Ac-PSMA-I&T), including TATCIST and an olaparib combination, all active but no longer recruiting ^[27][28][29]. AstraZeneca now runs AZD2265 (FPI-2265) in VECTRA-01, a Phase 3 against cabazitaxel, abiraterone and enzalutamide in PSMA-positive castration-resistant disease (NCT07611110, recruiting), plus a Phase 1b/2 platform pairing it with AZD9574 and docetaxel (NCT07590934) ^[22][23]. Bayer holds two Phase 1 alpha programmes, actinium-225-macropa-pelgifatamab (NCT06052306) and 225Ac-PSMA-Trillium (NCT06217822, recruiting) ^[24][25]. Convergent (Ac-225 rosopatamab, NCT06549465) ^[36], AdvanCell (lead-212, NCT05720130) ^[35], Clarity (copper-64/67 SAR-bisPSMA, NCT04868604) ^[34], Blue Earth (177Lu rhPSMA-10.1, NCT05413850) ^[37], Cellbion ^[43], Norroy ^[44], C Ray ^[45], VitsGen ^[46] and T.O.A.D. Oncology ^[47] fill out the isotope field; the chemistry itself remains actively contested ^[16]. Note that the 2023 Fusion filing's claim of superior alpha efficacy carries its own footnote — "Not a head-to-head comparison" ^[17].

The ARPI-intensification side, which Pluvicto now sits beside rather than after. Bayer runs a Phase 3 of darolutamide with ADT versus placebo with ADT in hormone-sensitive disease (NCT05794906) ^[26] and an Australian observational study of androgen-blocking medicines in mHSPC (NCT07223372, recruiting) ^[41]. Janssen runs a Phase 3 adding apalutamide to radiotherapy and an LHRH agonist in high-risk hormone-sensitive disease (NCT04557059) ^[42]. Sun Pharmaceutical runs a Phase 2 comparing abiraterone, enzalutamide and apalutamide in castrate-sensitive disease (NCT05422911, recruiting) ^[30]. Jiangsu Hengrui tests HRS-4357 head-to-head against ARPIs in PSMA-positive castration-resistant disease (NCT07311694, recruiting) ^[33].

Sequencing-dependent immunotherapy. Beyond Janux, Amgen's AMG 509 with abiraterone or enzalutamide (NCT04221542) ^[39], Regeneron's nezastomig with or without cemiplimab (NCT03972657) ^[38], GSK5458514 (NCT06990880) ^[40], and Janssen's JNJ-78278343 combinations — one of which, NCT06095089, lists lutetium Lu-177 vipivotide tetraxetan itself among its interventions ^[32].

Novartis is pruning inside its own house too: on 21-22 July 2026 it dropped a mid-stage radioligand asset while restating that the CEO's commitment to the modality is unchanged ^[9][10]. The asset is not named in the reporting retrieved. STAT separately reported on 2 June 2026 that a competing radiopharmaceutical showed promise in the post-Pluvicto setting; the agent and sponsor are not identified in the retrieved text ^[11].

What Prognyx could not verify

The registrational trial, its NCT number, its comparator and every efficacy figure; the exact approved indication wording, the named ARPI(s), the cycle count and the PSMA-positivity criterion; the identity of the withdrawn European application and its grounds; the discontinued Novartis Phase 2 asset; the STAT-reported competitor; the real-world discontinuation rate; and Novartis's lutetium-177 supply and US site count. No Novartis SEC filing covering this approval appears among the records reviewed, so the press-to-company-to-filing chain is closed only at the company step. Registry statuses cited here come from a snapshot dated 15 June 2026 and should be re-queried before anyone acts on them.

What to watch, and when

The label. The updated Prescribing Information on DailyMed and the supplement record and approval letter on Drugs@FDA for NDA 215833 are the only documents that will settle indication wording, ARPI specificity, cycle count and PSMA-positivity threshold ^[3][4]. No target action date, review designation or PDUFA-type clock for this supplement appears in any source reviewed, so Prognyx offers no date range here: the trigger is the posting itself, not a scheduled milestone, and it is the single highest-priority document in this file.

ARALU. A Phase 2, open-label, randomized study of Pluvicto added to standard-of-care darolutamide and ADT in hormone-sensitive metastatic disease, described in the European Urology Focus paper of 15 July 2026 ^[14]. No registry identifier appears in the sources reviewed. A randomized Phase 2 of a combination the FDA has just approved is either a redundancy or the sequencing detail the label leaves open — worth pinning down.

Resistance. The Jonsson Comprehensive Cancer Center's image-guided biopsy study of resistance mechanisms to 177Lu-PSMA in castration-resistant disease (NCT05398302) was recruiting as of the 15 June 2026 snapshot ^[31]. Earlier-line exposure changes what "resistant" means downstream.

Novartis's next results disclosure. The roughly $5 billion ambition reported in April ^[8] rests on a trade headline; the first company-primary statement on mHSPC uptake will be the test of whether a doubled label converts into doubled doses.

The now-what

1. Re-baseline every castration-resistant comparator. Any Phase 3 that assumed radioligand-naive patients in second- or third-line castration-resistant disease now has a stratification problem it did not have last week. Check whether prior 177Lu-PSMA exposure is an exclusion, a stratification factor, or silently neither.
2. Reprice "pre-Pluvicto" positioning. Programmes explicitly steered into the window before radioligand therapy ^[18] are targeting a window that just got narrower and moved earlier. Either move earlier again, or make the case in the post-radioligand setting — where at least one competitor is reportedly already generating data ^[11].
3. Underwrite the delivery constraint, not just the molecule. If theranostic-centre throughput is the binding constraint on a doubled population ^[15], the scarce asset is infusion capacity and isotope supply, not another PSMA ligand. That is a partnering thesis and a diligence question before it is a clinical one.

Verdict: high threat to every PSMA radioligand and PSMA T-cell engager built around Pluvicto's old line placement, but the magnitude is unpriceable until the label text and the registrational data land. Window to act: the weeks between now and the supplement posting on Drugs@FDA — after that, everyone is reading the same document.